Circulating endocannabinoidome signatures of disease activity in amyotrophic lateral sclerosis.
ALS
biomarker
endocannabinoid
inflammation
lipid
precision medicine
Journal
European journal of neurology
ISSN: 1468-1331
Titre abrégé: Eur J Neurol
Pays: England
ID NLM: 9506311
Informations de publication
Date de publication:
16 Aug 2024
16 Aug 2024
Historique:
revised:
26
05
2024
received:
23
03
2024
accepted:
19
06
2024
medline:
17
8
2024
pubmed:
17
8
2024
entrez:
17
8
2024
Statut:
aheadofprint
Résumé
Preclinical studies of amyotrophic lateral sclerosis (ALS) have shown altered endocannabinoid (eCB) signalling that may contribute to the disease. Results from human studies are sparse and inconclusive. The aim of this study was to determine the association between serum levels of eCBs or their congeners, the so-called endocannabinoidome, and disease status and activity in ALS patients. Serum concentrations of 2-arachidonoylglycerol and N-arachidonoylethanolamine (AEA), and AEA congeners palmitoylethanolamide (PEA), oleoylethanolamide (OEA), eicosapentaenoylethanolamide (EPEA), 2-docosahexaenoylglycerol (2-DHG) and docosahexaenoylethanolamide (DHEA) were measured in samples from 65 ALS patients, 32 healthy controls (HCs) and 16 neurological disease controls (NALS). A subset of 46 ALS patients underwent a longitudinal study. Disease activity and progression were correlated with eCB and congener levels. Most circulating mediators were higher in ALS than HCs (all p < 0.001), but not NALS. Across clinical stages, ALS patients showed increased levels of PEA, OEA and EPEA (all p < 0.02), which were confirmed by the longitudinal study (all p < 0.03). Serum PEA and OEA levels were independent predictors of survival and OEA levels were higher in patients complaining of appetite loss. Cluster analysis revealed two distinct profiles of circulating mediators associated with corresponding patterns of disease activity (severe vs. mild). Patients belonging to the 'severe' cluster showed significantly higher levels of OEA and PEA and lower levels of 2-DHG compared to NALS and HCs. Circulating endocannabinoidome profiles are indicative of disease activity, thus possibly paving the way to a personalized, rather than a 'one-fits-all', therapeutic approach targeting the endocannabinoidome.
Sections du résumé
BACKGROUND AND PURPOSE
OBJECTIVE
Preclinical studies of amyotrophic lateral sclerosis (ALS) have shown altered endocannabinoid (eCB) signalling that may contribute to the disease. Results from human studies are sparse and inconclusive. The aim of this study was to determine the association between serum levels of eCBs or their congeners, the so-called endocannabinoidome, and disease status and activity in ALS patients.
METHODS
METHODS
Serum concentrations of 2-arachidonoylglycerol and N-arachidonoylethanolamine (AEA), and AEA congeners palmitoylethanolamide (PEA), oleoylethanolamide (OEA), eicosapentaenoylethanolamide (EPEA), 2-docosahexaenoylglycerol (2-DHG) and docosahexaenoylethanolamide (DHEA) were measured in samples from 65 ALS patients, 32 healthy controls (HCs) and 16 neurological disease controls (NALS). A subset of 46 ALS patients underwent a longitudinal study. Disease activity and progression were correlated with eCB and congener levels.
RESULTS
RESULTS
Most circulating mediators were higher in ALS than HCs (all p < 0.001), but not NALS. Across clinical stages, ALS patients showed increased levels of PEA, OEA and EPEA (all p < 0.02), which were confirmed by the longitudinal study (all p < 0.03). Serum PEA and OEA levels were independent predictors of survival and OEA levels were higher in patients complaining of appetite loss. Cluster analysis revealed two distinct profiles of circulating mediators associated with corresponding patterns of disease activity (severe vs. mild). Patients belonging to the 'severe' cluster showed significantly higher levels of OEA and PEA and lower levels of 2-DHG compared to NALS and HCs.
CONCLUSION
CONCLUSIONS
Circulating endocannabinoidome profiles are indicative of disease activity, thus possibly paving the way to a personalized, rather than a 'one-fits-all', therapeutic approach targeting the endocannabinoidome.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e16400Subventions
Organisme : National Recovery and Resilience Plan (NRRP)
ID : E53D23019760001
Organisme : Ministry of University and Research (MUR)
ID : E53D23011330006
Informations de copyright
© 2024 The Author(s). European Journal of Neurology published by John Wiley & Sons Ltd on behalf of European Academy of Neurology.
Références
Masrori P, Van Damme P. Amyotrophic lateral sclerosis: a clinical review. Eur J Neurol. 2020 Oct;27(10):1918‐1929.
Shefner JM, Musaro A, Ngo ST, et al. Skeletal muscle in amyotrophic lateral sclerosis. Brain. 2023 Nov;146(11):4425‐4436.
Chiò A, Moglia C, Canosa A, et al. Cognitive impairment across ALS clinical stages in a population‐based cohort. Neurology. 2019;93(10):E984‐E994.
Dubbioso R, Provitera V, Pacella D, Santoro L, Manganelli F, Nolano M. Autonomic dysfunction is associated with disease progression and survival in amyotrophic lateral sclerosis: a prospective longitudinal cohort study. J Neurol. 2023;270(10):4968‐4977.
Nolano M, Provitera V, Caporaso G, et al. Skin innervation across amyotrophic lateral sclerosis clinical stages: new prognostic biomarkers. Brain. 2024;147(5):1740‐1750.
Burg T, Van Den Bosch L. Abnormal energy metabolism in ALS: a key player? Curr Opin Neurol. 2023;36(4):338‐345.
Beers DR, Appel SH. Immune dysregulation in amyotrophic lateral sclerosis: mechanisms and emerging therapies. Lancet Neurol. 2019;18(2):211‐220.
Staats KA, Borchelt DR, Tansey MG, Wymer J. Blood‐based biomarkers of inflammation in amyotrophic lateral sclerosis. Mol Neurodegener. 2022 Jan;17(1):11.
Hillard CJ. Circulating endocannabinoids: from whence do they come and where are they going? Neuropsychopharmacology. 2018;43(1):155‐172.
Cristino L, Bisogno T, Di Marzo V. Cannabinoids and the expanded endocannabinoid system in neurological disorders. Nat Rev Neurol. 2020;16(1):9‐29.
Witting A, Weydt P, Hong S, Kliot M, Mőller T, Stella N. Endocannabinoids accumulate in spinal cord of SOD1 G93A transgenic mice. J Neurochem. 2004;89(6):1555‐1557.
Pasquarelli N, Engelskirchen M, Hanselmann J, et al. Evaluation of monoacylglycerol lipase as a therapeutic target in a transgenic mouse model of ALS. Neuropharmacology. 2017;124:157‐169.
Bilsland LG, Dick JRT, Pryce G, et al. Increasing cannabinoid levels by pharmacological and genetic manipulation delays disease progression in SOD1 mice. FASEB J. 2006;20(7):1003‐1005.
Moreno‐Martet M, Espejo‐Porras F, Fernández‐Ruiz J, de Lago E. Changes in endocannabinoid receptors and enzymes in the spinal cord of SOD1 G93A transgenic mice and evaluation of a Sativex®‐like combination of phytocannabinoids: interest for future therapies in amyotrophic lateral sclerosis. CNS Neurosci Ther. 2014;20(9):809‐815.
Espejo‐Porras F, Piscitelli F, Verde R, et al. Changes in the endocannabinoid signaling system in CNS structures of TDP‐43 transgenic mice: relevance for a neuroprotective therapy in TDP‐43‐related disorders. J Neuroimmune Pharmacol. 2015;10(2):233‐244.
Iannotti FA. Cannabinoids, endocannabinoids, and synthetic cannabimimetic molecules in neuromuscular disorders. Int J Mol Sci. 2023;25(1):238.
Carter GT, McLaughlin RJ, Cuttler C, et al. Endocannabinoids and related lipids in serum from patients with amyotrophic lateral sclerosis. Muscle Nerve. 2021;63(1):120‐126.
Brooks BR, Miller RG, Swash M, Munsat TL. El Escorial revisited: revised criteria for the diagnosis of ALS. Amyotroph Lateral Scler Other Motor Neuron Disord. 2000;1(5):293‐299.
Cedarbaum JM, Stambler N, Malta E, et al. The ALSFRS‐R: a revised ALS functional rating scale that incorporates assessments of respiratory function. J Neurol Sci. 1999;169(1–2):13‐21.
Kimura F, Fujimura C, Ishida S, et al. Progression rate of ALSFRS‐R at time of diagnosis predicts survival time in ALS. Neurology. 2006;66(2):265‐267.
Dubbioso R, Spisto M, Hausdorff JM, et al. Cognitive impairment is associated with gait variability and fall risk in amyotrophic lateral sclerosis. Eur J Neurol. 2023;30(10):3056‐3067.
Strong MJ, Abrahams S, Goldstein LH, et al. Amyotrophic lateral sclerosis—frontotemporal spectrum disorder (ALS‐FTSD): revised diagnostic criteria. Amyotroph Lateral Scler Frontotemporal Degener. 2017;18(3–4):153‐174.
Moretta P, Spisto M, Ausiello FP, et al. Alteration of interoceptive sensitivity: expanding the spectrum of behavioural disorders in amyotrophic lateral sclerosis. Neurol Sci. 2022;43(9):5403‐5410.
De Lucia N, Ausiello FP, Spisto M, Manganelli F, Salvatore E, Dubbioso R. The emotional impact of COVID‐19 outbreak in amyotrophic lateral sclerosis patients: evaluation of depression, anxiety and interoceptive awareness. Neurol Sci. 2020;41(9):2339‐2341.
Ferraro PM, Gervino E, De Maria E, et al. Mild behavioral impairment as a potential marker of predementia risk states in motor neuron diseases. Eur J Neurol. 2023;30(1):47‐56.
Piscitelli F, Guida F, Luongo L, et al. Protective effects of N ‐oleoylglycine in a mouse model of mild traumatic brain injury. ACS Chem Neurosci. 2020;11(8):1117‐1128.
Kaufman L, Rousseeuw P. Finding groups in data: An introduction to cluster analysis. Wiley; 1990. https://doi.org/10.2307/2532178
Shoemaker JL, Seely KA, Reed RL, Crow JP, Prather PL. The CB2 cannabinoid agonist AM‐1241 prolongs survival in a transgenic mouse model of amyotrophic lateral sclerosis when initiated at symptom onset. J Neurochem. 2007;101(1):87‐98.
Rodríguez‐Cueto C, García‐Toscano L, Santos‐García I, et al. Targeting the CB2 receptor and other endocannabinoid elements to delay disease progression in amyotrophic lateral sclerosis. Br J Pharmacol. 2021;178(6):1373‐1387.
Yiangou Y, Facer P, Durrenberger P, et al. COX‐2, CB2 and P2X7‐immunoreactivities are increased in activated microglial cells/macrophages of multiple sclerosis and amyotrophic lateral sclerosis spinal cord. BMC Neurol. 2006;6(12):1‐14. doi:10.1186/1471-2377-6-12
Espejo‐Porras F, Fernández‐Ruiz J, de Lago E. Analysis of endocannabinoid receptors and enzymes in the post‐mortem motor cortex and spinal cord of amyotrophic lateral sclerosis patients. Amyotroph Lateral Scler Frontotemporal Degener. 2018;19(5–6):377‐386.
Ouali Alami N, Schurr C, Olde Heuvel F, et al. NF‐κB activation in astrocytes drives a stage‐specific beneficial neuroimmunological response in ALS. EMBO J. 2018;37(16):1‐23. doi:10.15252/embj.201798697
Huang D, Zhao Q, Liu H, Guo Y, Xu H. PPAR‐α agonist WY‐14643 inhibits LPS‐induced inflammation in synovial fibroblasts via NF‐kB pathway. J Mol Neurosci. 2016;59(4):544‐553.
Starinets A, Ponomarenko A, Tyrtyshnaia A, Manzhulo I. Synaptamide modulates glial and neurotransmitter activity in the spinal cord during neuropathic pain. J Chem Neuroanat. 2023;134:102361.
Kim H‐Y, Spector AA. N‐Docosahexaenoylethanolamine: a neurotrophic and neuroprotective metabolite of docosahexaenoic acid. Mol Asp Med. 2018;64:34‐44.
Palma E, Reyes‐Ruiz JM, Lopergolo D, et al. Acetylcholine receptors from human muscle as pharmacological targets for ALS therapy. Proc Natl Acad Sci. 2016;113(11):3060‐3065.
Pai AY, Wenziger C, Streja E, et al. Impact of circulating N‐acylethanolamine levels with clinical and laboratory end points in hemodialysis patients. Am J Nephrol. 2021;52(1):59‐68.
Rovito D, Giordano C, Vizza D, et al. Omega‐3 PUFA ethanolamides DHEA and EPEA induce autophagy through PPARγ activation in MCF‐7 breast cancer cells. J Cell Physiol. 2013;228(6):1314‐1322.
Balvers MGJ, Verhoeckx KCM, Witkamp RF. Development and validation of a quantitative method for the determination of 12 endocannabinoids and related compounds in human plasma using liquid chromatography–tandem mass spectrometry. J Chromatogr B. 2009;877(14–15):1583‐1590.
Lucanic M, Held JM, Vantipalli MC, et al. N‐acylethanolamine signalling mediates the effect of diet on lifespan in Caenorhabditis elegans. Nature. 2011;473(7346):226‐229.
Bjornevik K, Cortese M, Furtado JD, et al. Association of polyunsaturated fatty acids and clinical progression in patients with ALS. Neurology. 2023;101(7):e690‐e698. doi:10.1212/WNL.0000000000207485
Yip PK, Pizzasegola C, Gladman S, et al. The omega‐3 fatty acid eicosapentaenoic acid accelerates disease progression in a model of amyotrophic lateral sclerosis. PLoS One. 2013;8(4):e61626.
Zhao P, Ignacio S, Beattie EC, Abood ME. Altered presymptomatic AMPA and cannabinoid receptor trafficking in motor neurons of ALS model mice: implications for excitotoxicity. Eur J Neurosci. 2008;27(3):572‐579.
Rossi S, De Chiara V, Musella A, et al. Abnormal sensitivity of cannabinoid CB1 receptors in the striatum of mice with experimental amyotrophic lateral sclerosis. Amyotroph Lateral Scler. 2010 Jan;11(1–2):83‐90.
Simard M, Archambault A‐S, Lavoie J‐PC, Dumais É, Di Marzo V, Flamand N. Biosynthesis and metabolism of endocannabinoids and their congeners from the monoacylglycerol and N‐acyl‐ethanolamine families. Biochem Pharmacol. 2022;205:115261.
Gatta L, Piscitelli F, Giordano C, et al. Discovery of prostamide F2α and its role in inflammatory pain and dorsal horn nociceptive neuron hyperexcitability. PLoS One. 2012;7(2):e31111.
Mock ED, Gagestein B, van der Stelt M. Anandamide and other N‐acylethanolamines: a class of signaling lipids with therapeutic opportunities. Prog Lipid Res. 2023;89:101194.
Fu J, Gaetani S, Oveisi F, et al. Oleylethanolamide regulates feeding and body weight through activation of the nuclear receptor PPAR‐α. Nature. 2003;425(6953):90‐93.
Romano A, Gallelli CA, Koczwara JB, et al. Role of the area postrema in the hypophagic effects of oleoylethanolamide. Pharmacol Res. 2017;122:20‐34.
Venkatesan T, Zadvornova Y, Raff H, Hillard CJ. Endocannabinoid‐related lipids are increased during an episode of cyclic vomiting syndrome. Neurogastroenterol Motil. 2016;28(9):1409‐1418.